AstraZeneca and Japan's Daiichi Sankyo signed a potential multibillion-dollar deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
The medicine"has the potential to redefine breast cancer treatment," AstraZeneca's CEO said.
UK pharma giant AstraZeneca and Japan's Daiichi Sankyo have signed a potential multibillion-dollar collaboration to develop and sell Daiichi's cancer drug trastuzumab deruxtecan. Under the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development and commercialization costs for the drug worldwide, with Daiichi retaining exclusive rights in Japan.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug dealAstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daii...
Weiterlesen »
EU approves AstraZeneca's drug for adjunct use in Type-1 diabetesBritish drugmaker AstraZeneca Plc said on Monday the European Commission approve...
Weiterlesen »
Saudi Oil Firm Aramco Buys Stake in Chemicals Firm Sabic for $69 BillionSaudi Arabia’s national oil company has agreed to buy a majority stake in the kingdom’s petrochemicals firm for $69.1 billion, giving Crown Prince Mohammed bin Salman’s agenda a giant jolt of cash.
Weiterlesen »
BlackRock to buy French software firm eFront for $1.3 billion in cashWorld's biggest asset manager BlackRock Inc said on Friday it would buy Fre...
Weiterlesen »
This $2 Billion Financial Advisor Is His Firm's Head CoachAfter cutting his teeth at wirehouses including Merrill Lynch and Morgan Stanley, Hank McLarty built his own wealth management firm with a team of tax experts, trust and estate specialists, financial planning pros working alongside an investment strategy group.
Weiterlesen »
Saudi oil giant Aramco to pay $69.1 billion for majority stake in kingdom’s petrochemicals firm SabicSaudi Arabia’s national oil company has agreed to buy a majority stake in the kingdom’s petrochemicals firm for $69.1 billion, people familiar with the deal said, giving Crown Prince Mohammed bin Salman’s agenda a giant jolt of cash.
Weiterlesen »
Saudi Aramco reaches $69.1 billion deal to buy majority stake in petrochemicals firm SABICThe deal will see Saudi oil giant Aramco purchase the Public Investment Fund's 70-percent stake in SABIC.
Weiterlesen »
China video-streaming firm iQIYI targets raising $1.1 billion in convertible bondsChinese video-streaming service iQIYI Inc is looking to raise $1.05 billion in c...
Weiterlesen »
How this cancer drug has shown promise for the treatment of dementiaNot all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another.
Weiterlesen »
Silicon Valley millionaires — Quantum computing 101 — A $16 billion drug flopFor those of you who missed the first edition of this newsletter last week, I'm going to be sending out a weekly email highlighting some of the best reporting from our BI Prime coverage.
Weiterlesen »